Address
Astellas Venture Management LLC
PO Box 7585
Menlo Park, CA 94026
United States
Website
Industry
VCID: 2625
Profile
Corporate information
Official name
Astellas Venture Management LLC
Registration country
Official name
Astellas Venture Management LLC
Registration country
Investment activity status
Active investor
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Mission Bay Capital III |
16 Sep 2019 | Fund Closing Active |
||
|
Cleave Biosciences Inc Drug development company focused on novel targets in cellular protein homeostasis pathways |
United States | 1 Oct 2011 | Series A Active |
|
|
Fate Therapeutics Inc |
United States | 1 Nov 2009 | Series B Initial investment. Round participant. Active |
|
|
|
Nereus Pharmaceuticals Inc |
United States | 1 Aug 2007 | Series D |
|
|
|
DecImmune Therapeutics Inc Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction |
United States | N/A |
||
|
|
Cellzome AG A drug discovery and development company and a leader in the use of chemical proteomics technologies. |
Germany | N/A Active |
||
|
|
Renovar Inc |
United States | N/A |
||
|
|
Adhelex Technologies |
Canada | N/A Active |
||
|
|
Epizyme Inc Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs). |
United States | N/A |
||
|
|
Evolva Holding SA |
Switzerland | N/A |
||
|
|
Revivicor Inc |
United States | N/A |
||
|
Ironwood Pharmaceuticals Inc Entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. |
United States | N/A |
||
|
|
F2G Ltd |
United Kingdom | N/A |
||
|
|
CoMentis Inc |
United States | N/A |
||
|
|
Intradigm Corp |
United States | N/A |
||
|
|
PhaseBio Pharmaceuticals Inc |
United States | N/A |
||
|
|
Plexxikon Inc |
United States | N/A |
||
|
|
AkaRx Inc |
United States | N/A Active |
||
|
|
Inimex Pharmaceuticals Inc |
Canada | N/A |
||
|
|
FASgen Inc |
United States | N/A |